Literature DB >> 10933982

Amplification of transgene expression in vitro and in vivo using a novel inhibitor of histone deacetylase.

T Yamano1, K Ura, R Morishita, H Nakajima, M Monden, Y Kaneda.   

Abstract

Enhancement of transgene expression is an important issue in human gene therapy. Here we describe a novel system for enhancing transgene expression by cointroduction of plasmid DNA with FR901228, a water-soluble histone deacetylase inhibitor. When a luciferase expression vector was cointroduced into cells with FR901228, luciferase gene expression was enhanced 50-fold in the mouse melanoma cell line B16-F1 and 5200-fold in NIH3T3 cells in comparison to cells without the drug. Luciferase gene expression enhancement was dependent on both drug dose and treatment time. Acetylated histones increased in accordance with drug dose, and the activation of gene expression occurred at the transcriptional level. The stimulation of luciferase gene expression by FR901228 was also observed in a B16-F1 clone stably expressing luciferase. Cointroduction of the luciferase plasmid with FR901228 into a B16-F1 tumor mass activated luciferase gene expression 3- to 4-fold. Thus, activation of transgene expression by FR901228 may serve as a new tool for gene therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10933982     DOI: 10.1006/mthe.2000.0074

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  10 in total

1.  The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon.

Authors:  Christopher A Alvarez-Breckenridge; Jianhua Yu; Richard Price; Min Wei; Yan Wang; Michal O Nowicki; Yoonhee P Ha; Stephen Bergin; Christine Hwang; Soledad A Fernandez; Balveen Kaur; Michael A Caligiuri; E Antonio Chiocca
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

2.  Role for centromeric heterochromatin and PML nuclear bodies in the cellular response to foreign DNA.

Authors:  Cleo L Bishop; Michal Ramalho; Nachiket Nadkarni; Wing May Kong; Christopher F Higgins; Nina Krauzewicz
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

3.  Unintegrated HIV-1 DNAs are loaded with core and linker histones and transcriptionally silenced.

Authors:  Franziska K Geis; Stephen P Goff
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-04       Impact factor: 11.205

Review 4.  TRAIL gene therapy: from preclinical development to clinical application.

Authors:  Thomas S Griffith; Brittany Stokes; Tamara A Kucaba; James K Earel; Rebecca L VanOosten; Erik L Brincks; Lyse A Norian
Journal:  Curr Gene Ther       Date:  2009-02       Impact factor: 4.391

5.  Histone deacetylase inhibition enhances adenoviral vector transduction in inner ear tissue.

Authors:  A Taura; K Taura; Y H Choung; M Masuda; K Pak; E Chavez; A F Ryan
Journal:  Neuroscience       Date:  2010-01-06       Impact factor: 3.590

Review 6.  Clinical and experimental applications of sodium phenylbutyrate.

Authors:  Tommaso Iannitti; Beniamino Palmieri
Journal:  Drugs R D       Date:  2011-09-01

Review 7.  Long-term gene expression in dividing and nondividing cells using SV40-derived vectors.

Authors:  David S Strayer; Lokesh Agrawal; Pierre Cordelier; Bianling Liu; Jean-Pierre Louboutin; Elena Marusich; Hayley J McKee; Carmen N NiGongyi Ren; Marlene S Strayer
Journal:  Mol Biotechnol       Date:  2006-10       Impact factor: 2.860

8.  Splicing modulator FR901464 is a potential agent for colorectal cancer in combination therapy.

Authors:  Tomoki Yamano; Shuji Kubo; Aya Yano; Tomoko Kominato; Shino Tanaka; Masataka Ikeda; Naohiro Tomita
Journal:  Oncotarget       Date:  2019-01-08

9.  Activation of systemic antitumor immunity via TRAIL-induced apoptosis.

Authors:  Britnie R James; Thomas S Griffith
Journal:  Oncoimmunology       Date:  2012-10-01       Impact factor: 8.110

Review 10.  Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy.

Authors:  Carole Achard; Abera Surendran; Marie-Eve Wedge; Guy Ungerechts; John Bell; Carolina S Ilkow
Journal:  EBioMedicine       Date:  2018-04-23       Impact factor: 8.143

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.